BiotechTube

SOF + COPE

Pre-clinicalCompleted
2 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatitis C Virus Infection

Conditions

Hepatitis C Virus Infection

Trial Timeline

Sep 15, 2015 → Jun 5, 2017

NCT ID
NCT02537379

About SOF + COPE

SOF + COPE is a pre-clinical stage product being developed by Chugai Pharmaceutical for Hepatitis C Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02537379. Target conditions include Hepatitis C Virus Infection.

What happened to similar drugs?

20 of 20 similar drugs in Hepatitis C Virus Infection were approved

Approved (20) Terminated (8) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Pegylated Interferon + RibavirinAstellas PharmaApproved
✅Glecaprevir-pibrentasvirAbbVieApproved
✅ABT450r-ABT267-ABT333 +/- RibavirinAbbVieApproved
✅PTV/r/OBV/DSVAbbVieApproved
✅SOF/LDV (sofosbuvir/ledipasvir) + PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) + EBR/GZR (elbasvir/grazoprevir) + RibavirinAbbVieApproved
✅OBV/PTV/r and DSV + Placebo to match OBV/PTV/r and DSVAbbVieApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02537379Pre-clinicalCompleted

Competing Products

20 competing products in Hepatitis C Virus Infection

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
43
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
40
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
FK788Astellas PharmaPhase 2
35
MK-2248MerckPhase 1
29
Interferon alfacon-1Astellas PharmaPhase 3
40
Pegylated Interferon + RibavirinAstellas PharmaApproved
35
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir + MethadoneShionogiPhase 1
29
Clevudine + AdefovirEisaiPhase 3
40
KRN7000Kyowa KirinPhase 1/2
32